focus -WSS

focus

author：Wikipedia 2025-09-28 01:35:21 - browse：4326

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： As demand for Covid shots wanes, Moderna seeks its next success

focus

WSS

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

New Medicare drug pricing powers could soon be upended in court

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Drug repurposing or repositioning? The language matters

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Trump demands the U.S. pay no more for drugs than other countries … again

Medical records are filled with copy

What does generative AI mean for health care? We asked experts

Medicare details structure of new drug price negotiation program

After affirmative action ruling, medical educators look to 'holistic review'

Psychedelics group wrestles with new pharma identity

Hollywood unions extend contract negotiations for actors

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

entertainment

Affirmative action in medical school literally saved lives

Walensky prepares to leave CDC — and Congress — behind

New menopause drug shows promise in relief for hot flashes

Malaria cases in Florida and Texas: Here’s what you need to know

Trump demands the U.S. pay no more for drugs than other countries … again

Jerome Adams on the need for new antivirals for Covid

Wikipedia

focus

hotspot

focus